Thromboembolic events in immunomodulatory drug (IMiD)–sparing regimens for patients with newly diagnosed multiple myeloma (NDMM).

Authors: Gliceida M. Galarza Fortuna, John McCarron, Elena Nazarenko, Yizhe Xu, Kian University Medical Rahbari, Ming Lim, Kristen Marie Sanfilippo, Brian L. McClune, Ghulam Rehman Mohyuddin, Amandeep Godara, Douglas W. Sborov, Muhamed Baljevic

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e19530

Source: Full article

---

Abstract

e19530